VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 410 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2013. The put-call ratio across all filers is 0.62 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2016 | $6,232,000 | -73.0% | 236,946 | +4.5% | 0.76% | -67.9% |
| Q4 2015 | $23,059,000 | -40.1% | 226,848 | +5.2% | 2.36% | -38.9% |
| Q3 2015 | $38,477,000 | -19.3% | 215,702 | +0.5% | 3.87% | -5.2% |
| Q2 2015 | $47,690,000 | +11.4% | 214,675 | -0.4% | 4.08% | +14.9% |
| Q1 2015 | $42,802,000 | +49.7% | 215,498 | +7.9% | 3.55% | +49.7% |
| Q4 2014 | $28,590,000 | +9.1% | 199,779 | 0.0% | 2.37% | +11.8% |
| Q3 2014 | $26,211,000 | +4.0% | 199,779 | 0.0% | 2.12% | +5.5% |
| Q2 2014 | $25,196,000 | -4.3% | 199,779 | 0.0% | 2.01% | +5.1% |
| Q1 2014 | $26,337,000 | +12.3% | 199,779 | 0.0% | 1.91% | +4.3% |
| Q4 2013 | $23,454,000 | +12.1% | 199,779 | -0.4% | 1.83% | +8.5% |
| Q3 2013 | $20,919,000 | +21.2% | 200,504 | 0.0% | 1.69% | +14.6% |
| Q2 2013 | $17,259,000 | – | 200,504 | – | 1.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
| Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
| LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
| Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
| FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
| Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
| Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
| Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
| Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
| ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |